ENCYSIVE PHARMACEUTICALS (ENCY) discovers, develops and commercializes novel, synthetic, small molecule compounds to address unmet medical needs. The firm’s research focuses on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit the firm’s expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases.

Encysive develops Argatroban, which is used for the treatment of heparin-induced thrombocytopenia. It completed Phase 3 development of the endothelin receptor antagonist known as Thelin for the treatment pulmonary arterial hypertension. The drug was approved in March 2007 in Australia. The company provides research and development programs for various cardiovascular and inflammatory diseases.

Collaboration agreements: With Mitsubishi Pharma; Glaxo SmithKline, plc; and Schering-Plough.

The company was founded in 1989 and is headquartered in Houston, Texas.

To learn more visit: http://www.encysive.com.